CLIA establishes quality standards for all U.S. laboratory testing performed on humans. Labs are certified by complexity (waived, moderate, high) and inspected by CMS or accreditation organizations (CAP, COLA, Joint Commission). CLIA categorizes tests as waived, moderate complexity or high complexity, and labs must hold the matching certificate. CMS runs the program, FDA categorizes tests and CDC supports quality standards. Labs face proficiency testing, personnel requirements and inspections.

Why it matters

Moderate/high-complexity certification is required for most molecular and oncology testing. CLIA waiver is the gold standard for point-of-care market expansion.

Common pitfalls

•Misinterpreting "CLIA waived" as exempt from all regulatory oversight; waived tests still have specific conditions.
•Failing to properly document personnel qualifications for moderate and high complexity testing.
•Overlooking the need for a CLIA certificate even if performing a limited number of tests.
•Assuming that accreditation by an organization like CAP or COLA negates the need for CLIA compliance.

Sources

CMS CLIA · CMS
MedTech Europe - Facts & Figures · MedTech Europe
MedTech Dive · MedTech Dive

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.